FDA
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
-
-
-
-
-
-
-
Eupraxia reports positive symptom data from EoE trial
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

